Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

Fri, 09th Feb 2024 18:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Notes announcement by Kyverna Therapeutics regarding its pricing of a USD319 million initial public offering, upsized USD137 million above its initial estimate last week. Kyverna is a clinical-stage cell therapy biopharma company, in which RTW initially invested through a Series B funding round in early 2022. On the first day of trading, Kyverna's share price traded up by 36% to close at USD30.00 per share.

----------

Symphony Environmental Technologies PLC - Hertfordshire-based firm developing technology to make plastic biodegradable - Says that the General Court of the European Union found that the defendants didn't exceed "the limits of their discretion", so Symphony is not entitled to compensation. However, Symphony explains that the judgement was not an assessment of the effectiveness of the d2w technologies. Adds that the court didn't include further studies that have supported the technology, as well as the distinction between oxo-biodegradable and oxo-degradable plastics. Says that d2w technology has not been widely used in the EU for several years, and the lengthy legal process and judgment has "very little effect" on existing business.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes dispute with Stalicla SA, its partner in autism spectrum disorder and other neurodevelopmental disorders. Explains that in October 2022, Evgen licensed the rights for its lead asset, SFX-01, to Stalicla for up to USD160.5 million in milestone payments. An initial USD500,000 was paid upfront with the next anticipated payment of USD500,000 due on completion of the Evgen-sponsored human volunteer Phase 1 study. Evgen, having completed a Phase 1b study, believes the next payment is now due, and says it has formally implemented the dispute resolution process. It had not anticipated any milestone payments from Stalicla in its financial forecasting, and its cash runway remains unchanged.

----------

Substrate Artificial Inteligence SA - Madrid-based incubator of companies providing artificial intelligence products and services in fintech, agritech, energy, human resources, and health sectors - Signs investment deal with Indico Investments and Management SL, for a maximum of EUR2.0 million. The investment commitment, which expires on February 7, relates to the company's Class A shares. It will be carried out in tranches of EUR500,000, with a discount of 10%.

----------

DCI Advisors Ltd - British Virgin Islands-based real estate investment company - Says it has entered another loan agreement for EUR350,000 with a shareholder to provide additional working capital. The shareholder providing this loan previously entered into a loan agreement with DCI Advisors for EUR350,000 last October. To date, DCI has received seven loans of EUR350,000 each and two loans from funds managed by a single shareholder amounting to USD330,000 in aggregate.

----------

Apax Global Alpha Ltd - Guernsey-based investor in technology, services, healthcare, internet and consumer - Confirms that the offer of 120 pence in cash per Kin and Carta PLC share is final and will not be increased. In December, Apax said that a 'no increase statement' relating to its own offer price was no longer in effect and had been set aside, after Kin & Carta accepted an offer of 130p per share from Valtech, a company controlled by funds advised by London-based BC Partners LLP.

----------

Sutton Harbour Group PLC - Plymouth, England-based waterfront regeneration specialist - Notes press statement made by Plymouth City Council on Thursday, and confirms that it has received a letter from the Council alleging a breach of the Plymouth City Airport lease. Says that it is considering, in conjunction with its advisers, the contents of the letter, and will provide an update in due course.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
8 Jun 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
13 Feb 2020 16:17

Evgen Pharma, Rochester University To Advance SFX-01 For Trial

Evgen Pharma, Rochester University To Advance SFX-01 For Trial

Read more
6 Feb 2020 13:45

Evgen Pharma Hails "Positive" Data From Breast Cancer Drug Research

Evgen Pharma Hails "Positive" Data From Breast Cancer Drug Research

Read more
17 Dec 2019 15:35

Evgen Pharma narrows loss, foresees 'clinical success'

(Sharecast News) - Evgen Pharma on Tuesday reported a narrowed interim loss and said it was confident of clinical success as it continues to develop its SFX-01 treatment.

Read more
17 Dec 2019 11:28

Evgen Pharma Outlook Confident Amid Clinical Success And Trimmed Loss

Evgen Pharma Outlook Confident Amid Clinical Success And Trimmed Loss

Read more
10 Dec 2019 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
5 Dec 2019 16:36

Evgen Pharma to advance SFX-01 trial with University of Dundee

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has entered into a memorandum of understanding with the University of Dundee, it announced on Thursday, to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis (NASH) and liver fibrosis.

Read more
5 Dec 2019 15:19

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

Read more
11 Nov 2019 12:23

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

Read more
11 Nov 2019 10:22

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

Read more
11 Nov 2019 09:11

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Read more
23 Sep 2019 13:09

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Read more
23 Sep 2019 10:03

Evgen Pharma upbeat on latest news from SFX-01 studies

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Monday that five patients who participated in the 'STEM' trial received 'SFX-01' treatment for more than one year, with two of those patients continuing to be treated with SFX-01.

Read more
28 Aug 2019 14:30

Evgen Pharma completes patient study visits in 'SAS' phase 2 trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that the last study visit for the last patient entered in the double-blind, placebo-controlled 'SAS' phase 2 clinical trial has taken place.

Read more
28 Aug 2019 12:06

Evgen Pharma Receives Last Patient For Stroke Treatment Drug Trial

(Alliance News) - Evgen Pharma PLC said Wednesday it has entered its last patient in the double-blind, placebo-controlled SAS Phase II clinical trial that is testing its SFX-01 product, aimed at a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.